https://www.selleckchem.com/pr....oducts/ezatiostat.ht
may not be clinically significant. Robust imaging biomarkers are needed for risk stratification in stage I lung adenocarcinoma patients in order to select optimal treatment regimen. We aimed to construct and validate a radiomics nomogram for predicting the disease-free survival (DFS) of patients with resected stage I lung adenocarcinoma, and further identifying candidates benefit from adjuvant chemotherapy (ACT). Using radiomics approach, we analyzed 554 patients' computed tomography (CT) images from three multicenter cohorts. Progno
Like
Comment
Share
